Skip to main content
Caplight Logo









Avstera Therapeutics

Avstera Therapeutics

Private
Malvern, PennsylvaniaHealthcare & Life Scienceshttps://avstera.com/

Last Round

Accelerator

Oct 13, 2023

Total Funding Raised

$9.55M

Company Overview

Avstera Therapeutics is a biotechnology company that develops therapies to address the significant needs of advanced cancer patients with limited or no treatment options.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

HDAC6 inhibitorcancer therapysolid tumor therapyoncology therapeuticstumor microenvironmentmacrophage modulationcancer immunotherapysmall molecule therapytumor-associated macrophagesTAMsmacrophage cell therapyclinical stage biotechorphan drugmRNA cancer vaccinemelanoma therapymyeloid target discovery

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Avstera Therapeutics Comparables

Compare Avstera Therapeutics with similar companies based on industry and business-model similarity.

Avstera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
SIRPant Immunotherapeutics
80%
United Immunity, Co., Ltd.
78%
Jubilant Pharmova Limited
78%

Avstera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
AcceleratorOct 13, 2023
Series AOct 2, 2023
SeedNov 9, 2022

Avstera Therapeutics Investors

Notable investors and investment history

Avstera Therapeutics investors
InvestorRounds
University of Pennsylvania Office of InvestmentsSeed
Togo VenturesSeries A
Backswing VenturesSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 18, 2026

    Monthly visitors grew 110% MoM, reaching 1.7K.

  • Jul 2, 2025

    Monthly visitors increased 2623% from 30 to 817.

Avstera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Avstera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Avstera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersMalvern, Pennsylvania
Employee Range5
Year Founded2020
Last FundingOct 13, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?